Latest Singulair Lawsuit Updates

At Drugwatch, senior writer Michelle Lamas breaks down the latest news in lawsuits filed against Merck claiming the asthma drug caused serious mental health side effects in users — including many children:

“According to our research, there were 247 lawsuits when the cases were first consolidated in New Jersey in March 2022. There is no current publicly available case list from the New Jersey MCL. It’s difficult to know exactly how many cases there are now. By researching court documents and talking to lawyers, we’ve detailed the most recent updates. . . .

Why Are Singulair Lawsuits Being Filed?

Plaintiffs, including the parents of children who suffered psychiatric disorders after taking Singulair, are filing lawsuits that accuse Merck of designing a defective drug, negligence and failure to warn about the risk of mental problems. . . . 

Montelukast, Singulair’s active ingredient, has gone through extensive testing prior to being approved in 1998 through today, and these studies showed linked using the drug to neuropsychiatric events, according to court documents we researched.

We also analyzed the FDA’s adverse event reporting system, and reports of Singulair psychiatric adverse event reports have only increased in recent years, especially in 2021, 2022 and 2023. It’s important to note that the FDA cannot prove these adverse events were caused by Singulair because they are voluntary reports.

Singulair is prescribed for severe allergies and asthma in adults and children. Out of 7,944 psychiatric adverse events reported as the FDA’s latest available information released on March 31, 2024, the age group of two months to 17 years had 2,872 reports.

In March 2020, the U.S. Food and Drug Administration added a Singulair boxed warning, its strongest label warning, for serious mental health side effects. Prior to this label change, there were insufficient warnings, according to lawsuits.”

Article →***

More from Around the Web